Inhibition of Epo signalling, by the injection of an anti-Epo monoclonal antibody or a soluble form of EpoR, results in delay of tumour growth in ovarian and uterine cancers.18 In nude mice, Yasuda et al. 26 blocked the Epo signalling in xenografts of two representative cell lines by intraperitoneal injections of EpoR antagonist and found inhibition of angiogenesis and survival of tumour cells leading to destruction of tumour masses. The gene discussed is EPO; the disease is uterine cancer.